SJGA
ANIX icon

Stephen J. Garry & Associates’s Anixa Biosciences ANIX Stock Holding History

Stephen J. Garry & Associates’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,080
Closed -$31.4K – 52
2025
Q4 		$31.4K Hold
10,080
– – 0.02% 51
2025
Q3 		$33.3K Hold
10,080
– – 0.03% 51
2025
Q2 		$33.3K Hold
10,080
– – 0.03% 47
2025
Q1 		$28.8K Hold
10,080
– – 0.03% 43
2024
Q4 		$23.4K Hold
10,080
– – 0.02% 44
2024
Q3 		$31.8K Hold
10,080
– – 0.03% 40
2024
Q2 		$22.3K Hold
10,080
– – 0.02% 40
2024
Q1 		$31.4K Hold
10,080
– – 0.03% 41
2023
Q4 		$39.1K Buy
+10,080
New +$34K 0.04% 39

Other funds holding ANIX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Stephen J. Garry & Associates's ANIX Position: Q1 2026 in Review

Stephen J. Garry & Associates sold out of Anixa Biosciences (ANIX) in Q1 2026, closing a stake of 10,080 shares — an estimated $31.4K sold.

Stephen J. Garry & Associates first reported a position in ANIX in Q4 2023 and held it in 9 quarters. The position peaked at $39.1K in Q4 2023. 60 funds tracked by Wall St. Rank hold ANIX as of Q1 2026.

  • Stephen J. Garry & Associates reported no remaining Anixa Biosciences position as of Q1 2026 after selling out during the quarter.
  • Stephen J. Garry & Associates sold 10,080 Anixa Biosciences shares in Q1 2026, an estimated $31.4K.
  • Stephen J. Garry & Associates first reported a position in Anixa Biosciences in Q4 2023 and held it in 9 quarters.
  • Stephen J. Garry & Associates's Anixa Biosciences position peaked at $39.1K in Q4 2023.
  • 60 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2026.

Based on Stephen J. Garry & Associates's 13F filing for Q1 2026, filed 16 Apr 2026.